MRG 007
Alternative Names: MRG-007Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator Lepu Biopharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal cancer; Solid tumours
Most Recent Events
- 17 Feb 2025 Preclinical trials in Solid tumours in China (Parenteral), before February 2025 (Lepu Biopharma pipeline, February 2025)
- 23 Jan 2025 Lepu Biopharma and ArriVent BioPharma agree to co-promote MRG 007 in China for Gastrointestinal cancer
- 23 Jan 2025 Preclinical trials in Gastrointestinal cancer in China (Parenteral) prior to January 2025